Patents by Inventor Yao-tseng Chen

Yao-tseng Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies specific for SSX proteins
    Publication number: 20030023057
    Abstract: The invention relates to members of the SSX family of genes, as well as their uses.
    Type: Application
    Filed: October 11, 2001
    Publication date: January 30, 2003
    Inventors: Ali O. Gure, Ozlem Tureci, Ugur Sahin, Solam Tsang, Matthew J. Scanlan, Alexander Knuth, Michael Pfreundschuh, Lloyd J. Old, Yao-Tseng Chen
  • Isolated cancer associated antigens NY-MEL 1 and NY-MEL 3, peptides based thereon, and their uses
    Publication number: 20030017547
    Abstract: The invention relates to isolated, cancer associated antigens, nucleic acid molecules, and various uses thereof.
    Type: Application
    Filed: May 21, 2002
    Publication date: January 23, 2003
    Inventors: Dirk Jager, Elizabeth Stockert, Matthew Scanlan, Ali Gure, Elke Jager, Alexander Knuth, Lloyd Old, Yao-Tseng Chen
  • Isolated peptides which bind to HLA-C molecules and uses thereof
    Patent number: 6506875
    Abstract: The invention teaches peptide epitopes which bind to HLA-Cw3 and HLA-Cw6 molecules on the surface of cells. The peptides are useful diagnostically and therapeutically, as are DNA molecules which encode them, and the cytolytic T lymphocytes specific to the HLA/peptide complexes. Also a feature of the invention is a method for identifying relevant molecules such as those described herein, in a system that uses stimulation and restimulation using different viral vectors.
    Type: Grant
    Filed: September 26, 2000
    Date of Patent: January 14, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Sacha Gnjatic, Lloyd J. Old, Yasuhiro Nagata, Elke Jager, Yao-Tseng Chen, Alexander Knuth
  • Isolated nucleic acid molecules encoding ESO-1 peptides and uses thereof
    Publication number: 20020164665
    Abstract: The invention relates to antibodies which bind to the cancer associated antigen NY-ESO-1. Both polyclonal and monoclonal antibodies are part of the invention, as are chimeric forms of the antibodies, and binding portions of antibodies. Uses of these antibodies are described. Also described are truncated, recombinant forms of the cancer associated antigen.
    Type: Application
    Filed: December 17, 2001
    Publication date: November 7, 2002
    Inventors: Elisabeth Stockert, Elke Jager, Yao-Tseng Chen, Matthew Scanlan, Knuth Alexander, Lloyd J. Old
  • Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
    Patent number: 6448073
    Abstract: The invention relates to isolated, cancer associated antigens, nucleic acid molecules, and various uses thereof.
    Type: Grant
    Filed: January 28, 2000
    Date of Patent: September 10, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Dirk Jager, Elizabeth Stockert, Matthew Scanlan, Ali Gure, Elke Jager, Alexander Knuth, Lloyd Old, Yao-tseng Chen
  • Renal cancer associated antigens and uses therefor
    Patent number: 6440663
    Abstract: Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in renal cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with renal cancer. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: August 27, 2002
    Assignees: Ludwig Institute for Cancer Research, The New York Hospital-Cornell Medical Center
    Inventors: Matthew J. Scanlan, Elisabeth Stockert, Yao-Tseng Chen, Lloyd J. Old, Elke Jager, Alex Knuth
  • Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
    Publication number: 20020111470
    Abstract: The invention relates to the isolation of a nucleic acid molecule which encodes a cancer associated antigen. Also a part of the invention is the antigen itself, and the uses of the nucleic acid molecule and the antigen, and peptides derived from it.
    Type: Application
    Filed: July 6, 2001
    Publication date: August 15, 2002
    Inventors: Yao-Tseng Chen, Ali Gure, Solam Tsang, Elisabeth Stockert, Elke Jager, Knuth Alexander, Lloyd J. Old
  • Isolated nucleic acid molecules associated with colon, renal, and stomach cancer and methods of using these
    Patent number: 6403373
    Abstract: Various molecules associated with cancer are disclosed. The invention also discloses diagnostic and therapeutic methods based upon these molecules.
    Type: Grant
    Filed: June 22, 1998
    Date of Patent: June 11, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Matthew J. Scanlan, Yao-Tseng Chen, Elisabeth Stockert, Lloyd J. Old
  • Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof
    Patent number: 6355256
    Abstract: The invention involves the combination of Interleukin-12 with p53 derived peptides and an adjuvant, preferably QS-21. It is found that this combination provokes a surprisingly strong immune response. Further, in an accepted in vivo model, the use of compositions containing these three ingredients led to diamatic decreases in the growth of induced tumors, thus suggesting a therapeutic regime.
    Type: Grant
    Filed: March 22, 1995
    Date of Patent: March 12, 2002
    Assignees: Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center
    Inventors: Yuji Noguchi, Yao-tseng Chen, Lloyd J. Old
  • Truncated forms of NY-ESO-1 protein
    Publication number: 20020010321
    Abstract: The invention relates to antibodies which bind to the cancer associated antigen NY-ESO-1. Both polyclonal and monoclonal antibodies are part of the invention, as are chimeric forms of the antibodies, and binding portions of antibodies. Uses of these antibodies are described. Also described are truncated, recombinant forms of the cancer associated antigen.
    Type: Application
    Filed: December 29, 2000
    Publication date: January 24, 2002
    Inventors: Yao-tseng Chen, Matthew Scanlan, Ali O. Gure, Lloyd J. Old, Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh, Elisabeth Stockert, Elke Jager, Knuth Alexander
  • SSX family proteins
    Patent number: 6339140
    Abstract: The invention relates to members of the SSX family of genes, as well as their uses.
    Type: Grant
    Filed: March 1, 2001
    Date of Patent: January 15, 2002
    Assignees: Ludwig Institute for Cancer Research, Cornell Medical Research Foundation, Memorial Sloan Kettering Cancer Center
    Inventors: Ali O. Gure, Ozlem Tureci, Ugur Sahin, Solam Tsang, Matthew J. Scanlan, Alexander Knuth, Michael Pfreundschuh, Lloyd J. Old, Yao-Tseng Chen
  • Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
    Patent number: 6338947
    Abstract: The invention relates to assays for determining breast cancer or melanoma. It has been found that the accuracy of such assays can be improved by assaying samples for three or more known tumor rejection antigen precursors. For breast cancer, the tumor rejection antigen precursors known as SCP-1, NY-ESO-1, and SSX-2 are assayed. For melanoma, SSX-2, NY-ESO-1, and MAGE-3 are assayed. Additional known tumor rejection antigen precursors can also be determined to confirm the assays. It is preferred to carry these out via polymerase chain reactions.
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: January 15, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ugur Sahin, Özlem Türeci, Yao-Tseng Chen, Lloyd J. Old, Michael Pfreundschuh
  • Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
    Patent number: 6297364
    Abstract: The invention relates to the isolation of a nucleic acid molecule which encodes a cancer associated antigen. Also a part of the invention is the antigen itself, and the uses of the nucleic acid molecule and the antigen, and peptides derived from it.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: October 2, 2001
    Assignees: Ludwig Institute For Cancer Research, Cornell Research Foundation, Inc., Memorial Sloan-Kettering Cancer Center
    Inventors: Yao-Tseng Chen, Ali Gure, Solam Tsang, Elisabeth Stockert, Elke Jäger, Knuth Alexander, Lloyd J. Old
  • Isolated nucleic acid molecules encoding SSX family members and thereof
    Patent number: 6291658
    Abstract: The invention relates to members of the SSX family of genes, as well as their uses.
    Type: Grant
    Filed: May 5, 1997
    Date of Patent: September 18, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ali O. Gure, Ozlem Tureci, Ugur Sahin, Solam Tsang, Matthew J. Scanlan, Alexander Knuth, Michael Pfreundschuh, Lloyd J. Old, Yao-Tseng Chen
  • Methods for determining presence of cancer in a sample by determining expression of an SSX gene
    Patent number: 6287756
    Abstract: The invention relates to members of the SSX family of genes, as well as to their uses.
    Type: Grant
    Filed: June 26, 1998
    Date of Patent: September 11, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Özlem Türeci, Yao-Tseng Chen, Ugur Sahin, Ali O. Gure, Lloyd J. Old, Michael Pfreundschuh
  • Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
    Patent number: 6274145
    Abstract: The invention relates to the isolation of a nucleic acid molecule which encodes a cancer associated antigen. Also a part of the invention is the antigen itself, and the uses of the nucleic acid molecule and the antigen, and peptides derived from it.
    Type: Grant
    Filed: September 15, 1997
    Date of Patent: August 14, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Yao-tseng Chen, Matthew Scanlan, Ali Guré, Lloyd J. Old, Elke Jäger, Knuth Alexander, Jan W. Drijfhout, Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh
  • Isolated nucleic acid molecule encoding an esophageal cancer associated antigen
    Patent number: 6255470
    Abstract: The invention relates to the isolation of a nucleic acid molecule which encodes an esophageal cancer associated antigen. Also a part of the invention is the antigen itself, and the uses of the nucleic acid molecule and the antigen.
    Type: Grant
    Filed: September 14, 1999
    Date of Patent: July 3, 2001
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Yao-tseng Chen, Matthew Scanlan, Ali Gure, Lloyd J. Old
  • Antibodies which bind to NY-ESO-1 cancer associated proteins, and hybridomas which produce these antibodies
    Patent number: 6252052
    Abstract: The invention relates to antibodies which bind to the cancer associated antigen NY-ESO-1. Both polyclonal and monoclonal antibodies are part of the invention, as are chimeric forms of the antibodies, and binding portions of antibodies. Uses of these antibodies are described. Also described are truncated, recombinant forms of the cancer associated antigen.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: June 26, 2001
    Assignees: Cornell Research Foundation, Inc, Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center
    Inventors: Elisabeth Stockert, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Knuth Alexander, Lloyd J. Old
  • Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
    Patent number: 6140050
    Abstract: The invention relates to assays for determining breast cancer or melanoma. It has been found that the accuracy of such assays can be improved by assaying samples for three or more known tumor rejection antigen precursors. For breast cancer, the tumor rejection antigen precursors known as SCP-1, NY-ESO-1, and SSX-2 are assayed. For melanoma, SSX-2, NY-ESO-1, and MAGE-3 are assayed. Additional known tumor rejection antigen precursors can also be determined to confirm the assays. It is preferred to carry these out via polymerase chain reactions.
    Type: Grant
    Filed: June 26, 1998
    Date of Patent: October 31, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ugur Sahin, Ozlem Tureci, Yao-Tseng Chen, Lloyd J. Old, Michael Pfreundschuh
  • Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
    Patent number: 6069233
    Abstract: The invention relates to the isolation of a nucleic acid molecule which encodes an esophageal cancer associated antigen. Also a part of the invention is the antigen itself, and the uses of the nucleic acid molecule and the antigen.
    Type: Grant
    Filed: January 26, 1998
    Date of Patent: May 30, 2000
    Assignees: Memorial Sloan-Kettering Cancer Center, Cornell Research Foundation, Ludwig Institute for Cancer Research
    Inventors: Yao-tseng Chen, Matthew Scanlan, Ali O. Gure, Lloyd J. Old, Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh